
Pharmacally
Desmoid Tumors
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Desmoid Tumors
Clinical TrialsParabilis Reports 100% Disease Control With Zolucatetide in Desmoid TumorsParabilis Medicines reported a 72.2% objective response rate at 32 weeks with investigational zolucatetide in patients with desmoid tumors.Fact-Checked
Health TidingsImmunome’s Varegacestat NDA Accepted by FDA for Desmoid TumorsThe FDA has accepted Immunome’s New Drug Application for varegacestat, an investigational once-daily oral gamma secretase inhibitor for adults with desmoid tumors.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.